Previous 10 | Next 10 |
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at the Sidoti Fall Small Cap Investor Conference taking...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Baird’s 2022 Global Healthcare Conference taking place September 13-14, 2022, at...
ILDsym will enable new software and services revenue by aiding development of therapies for the treatment of patients with ILD as a complication of systemic sclerosis Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and se...
Several posters and oral presentations involved the use of MonolixSuite® Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five s...
Simulations Plus ( NASDAQ: SLP ) had declared $0.06/share quarterly dividend , in line with previous. Payable Aug. 1; for shareholders of record July 25; ex-div July 22. See SLP Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: ...
Tenured employees support St. Jude in finding cures and saving children Simulations Plus (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to St. Jude Childr...
Investments made to accelerate adoption of new approaches through strategic partnerships with organizations globally Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, rec...
AlphaFold is a leading open-source AI program that aids researchers in visualizing protein structures. Applications are diverse and reduce research time across the healthcare industry and academia. The program certainly is a gift to our future health, but the open source nature an...
SLP reported its Q3 earnings which beat expectations. The company is benefiting from increasing market adoption of its best-in-class drug development modeling tools. Shares are pricey but we see more upside in the stock supported by a long-term growth runway and expanding customer...
Image source: The Motley Fool. Simulations Plus, Inc. (NASDAQ: SLP) Q3 2022 Earnings Call Jul 06, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Simulations Plus, Inc. (SLP) Q3 2022 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...